Literature DB >> 8052385

AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo.

Y Takamiya1, H Brem, J Ojeifo, T Mineta, R L Martuza.   

Abstract

Glioblastoma is the most malignant primary brain tumor. Inhibition of angiogenesis is one potential strategy for treating this fatal hypervascular tumor. AGM-1470 (also called TNP-470), a novel, potent, fungus-derived inhibitor of angiogenesis, was tested on the growth of human glioblastoma cells in culture and on the growth of the tumor in nude mice. In nude mice with subrenally implanted U-87 MG glioblastomas, AGM-1470 significantly inhibited tumor growth (P < 0.01), and in nude mice with intracranial U-87 MG glioblastomas, AGM-1470 prolonged survival. In addition to its expected action as an angiogenesis inhibitor, AGM-1470 also directly inhibited U-87 MG cells in culture at concentrations similar to those that inhibited endothelial cells. The combined inhibition of glioblastoma cell mitosis and of glioblastoma-induced neovascularization suggests that AGM-1470 should be considered for further investigation in the treatment of this fatal tumor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8052385     DOI: 10.1227/00006123-199405000-00013

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  15 in total

Review 1.  Novel delivery strategies for glioblastoma.

Authors:  Jiangbing Zhou; Kofi-Buaku Atsina; Benjamin T Himes; Garth W Strohbehn; W Mark Saltzman
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  Inhibitory effects of TNP-470 in combination with BCNU on tumor growth of human glioblastoma xenografts.

Authors:  Dongxiao Yao; Hongyang Zhao; Fangcheng Zhang; Jian Chen; Xiaobing Jiang; Xianli Zhu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

Review 3.  Angiogenesis in brain tumors; pathobiological and clinical aspects.

Authors:  P Wesseling; D J Ruiter; P C Burger
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

4.  The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2.

Authors:  N Sin; L Meng; M Q Wang; J J Wen; W G Bornmann; C M Crews
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

Review 5.  An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.

Authors:  W J Gradishar
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

6.  The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice.

Authors:  H J Bernsen; P F Rijken; H Peters; H Bakker; A J van der Kogel
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

7.  Antitumor effect of TNP-470 is not associated to decrease of angiogenesis in an experimental malignant neuroectodermic tumor.

Authors:  C Morales; M Zurita; J Vaquero
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

8.  Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470.

Authors:  T Yazaki; Y Takamiya; P C Costello; T Mineta; A G Menon; S D Rabkin; R L Martuza
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

9.  An orally delivered small-molecule formulation with antiangiogenic and anticancer activity.

Authors:  Ofra Benny; Ofer Fainaru; Avner Adini; Flavia Cassiola; Lauren Bazinet; Irit Adini; Elke Pravda; Yaakov Nahmias; Samir Koirala; Gabriel Corfas; Robert J D'Amato; Judah Folkman
Journal:  Nat Biotechnol       Date:  2008-06-29       Impact factor: 54.908

Review 10.  Novel technologies for antiangiogenic drug delivery in the brain.

Authors:  Ofra Benny; Pouya Pakneshan
Journal:  Cell Adh Migr       Date:  2009-04-06       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.